As a provider accredited by the ACCME, it is the policy of NL
Communications to require the disclosure of any significant financial
interest or any other relationship the sponsor or faculty members
have with the manufacturer(s) of any commercial product(s) discussed
in an educational presentation. The presenting faculty reported
the following:
| Pharmaceutical
agents discussed in this program |
| GENERIC |
TRADE |
MANUFACTURER |
| aminoglutethimide |
Cytadren® |
Novartis Pharmaceuticals Corporation |
 |
| anastrozole |
Arimidex® |
AstraZeneca Pharmaceuticals LP |
|
| bevacizumab |
AvastinTM |
Genentech Inc. |
|
| capecitabine |
Xeloda® |
Roche Laboratories Inc. |
|
| carboplatin |
Paraplatin® |
Bristol-Myers Squibb Company |
|
| cisplatin |
Platinol® |
Bristol-Myers Squibb Company |
| cyclophosphamide |
Cytoxan® |
Bristol-Myers Squibb Company,
Neosar® Pharmacia Corporation |
|
| docetaxel |
Taxotere® |
Aventis Pharmaceuticals Inc. |
|
| doxorubicin |
Adriamycin® |
Pharmacia Corporation |
|
| doxorubicin HCL liposome injection |
Doxil® |
Ortho Biotech Products Inc. |
|
| exemestane |
Aromasin® |
Pharmacia Corporation |
|
| filgrastim |
Neupogen® |
Amgen Inc. |
|
| fluorouracil, 5FU |
— |
Various |
|
| fulvestrant |
Faslodex® |
AstraZeneca Pharmaceuticals LP |
|
| gemcitabine |
Gemzar® |
Eli Lilly & Company |
|
| gefitinib |
Iressa® |
AstraZeneca Pharmaceuticals LP |
|
| goserelin |
Zoladex® |
AstraZeneca Pharmaceuticals LP |
|
| letrozole |
Femara® |
Novartis Pharmaceuticals Corporation |
|
| megestrol acetate |
Megace® |
Bristol-Myers Squibb Company |
|
| methotrexate |
— |
Various |
|
| paclitaxel |
Taxol® |
Bristol-Myers Squibb Company |
|
| pegfilgrastim |
Neulasta® |
Amgen Inc. |
|
| tamoxifen citrate |
Nolvadex® |
AstraZeneca Pharmaceuticals LP |
|
| trastuzumab |
Herceptin® |
Genentech Inc. |
|
| vinorelbine |
Navelbine® |
GlaxoSmithKline |
|
| zoledronate |
Zometa® |
Novartis Pharmaceuticals Corporation |
| |
|
|
This educational activity contains discussion of published and/or
investigational uses of agents that are not indicated by the FDA.
NL Communications, Inc. does not recommend the use of any agent
outside of the labeled indications. Please refer to the official
prescribing information for each product for discussion of approved
indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those
of the publisher or grantor.
